07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Pivotal trial data

The open-label, Australian pivotal REMEDEE trial in 183 patients with de novo native coronary artery stenosis showed that OrbusNeich's Combo Bio-engineered Sirolimus Eluting stent met the primary endpoint of non-inferiority to the Taxus Liberte paclitaxel-eluting...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Ion paclitaxel-eluting coronary stent regulatory update

FDA approved the Ion and Taxus Liberte paclitaxel-eluting coronary stent systems from Boston Scientific to treat acute myocardial infarction. Both are next-generation drug-eluting coronary platinum chromium alloy stent systems. Taxus Liberte already is approved in...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

Combo Bio-engineered Sirolimus Eluting Stent: Completed Phase II enrollment

OrbusNeich completed enrollment of 183 patients in the open-label, international Phase II REMEDEE trial to compare its Combo Bio-engineered stent vs. Taxus Liberte paclitaxel-eluting stent from Boston Scientific Corp. (NYSE:BSX, Natick, Mass.). OrbusNeich's stent utilizes...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Taxus Liberte: Additional data

Additional data from the ATLAS Long Lesion study showed that the Taxus Liberte Long Stent significantly reduced the rate of target-vessel myocardial infarction (MI) (2.6% vs. 12.9%, p=0.02) and target-vessel non-Q-wave MI (2.6% vs. 11.3%,...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Taxus Liberte: Additional data

Additional data from the ATLAS Small Vessel study showed that Taxus Liberte significantly reduced the rates of target lesion revascularization (TLR) at 4 years vs. Taxus Express (10.8% vs. 23.8%, p=0.008). Taxus Liberte also significantly...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Taxus Liberte: Additional data

Additional data from the ATLAS trial in 871 patients showed that Taxus Liberte and Taxus Express led to similar rates of target lesion revascularization (TLR) at 5 years (11% vs. 11.5%, p=0.72). Rates of cardiac...
07:00 , Jun 7, 2010 |  BC Week In Review  |  Clinical News

Xience V: Post-marketing study data

In the international SPIRIT V Diabetes trial in 324 patients with diabetes, Xience V was superior to Taxus Liberte on the primary endpoint of in-stent late loss at 9 months (0.19 vs. 0.39 mm, p=0.0001)....
07:00 , Jun 7, 2010 |  BC Week In Review  |  Clinical News

Nevo sirolimus-eluting coronary stent: Additional pivotal trial data

Additional data from the international, pivotal NEVO RES I trial in 394 patients showed that at 12 months, there were no episodes of stent thrombosis in the Nevo arm vs. 2 events in the Taxus...
07:00 , Mar 22, 2010 |  BC Week In Review  |  Clinical News

Taxus Express paclitaxel-eluting stent system: Additional Phase III data

One-year follow-up data from a subgroup of diabetic patients experiencing acute MI (AMI) in the single-blind, international Phase III HORIZONS AMI trial showed that Taxus Express2 paclitaxel-eluting stent system significantly reduced ischemia-driven TLR by 54%...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

Boston Scientific, J&J cardiovascular news

Boston Scientific will pay $1.73 billion to Johnson & Johnson 's Cordis Corp. subsidiary to settle three patent disputes covering cardiovascular stents. The first dispute alleged Boston Scientific's Express, Taxus Express and Liberte stents infringed...